Lyon Joseph Douglas 4

What Happened

• Lyon Joseph Douglas, Corcept Therapeutics’ Chief Accounting & Technology Officer, was granted a derivative award for 140,000 shares on February 27, 2026. The Form 4 reports an acquisition price of $0.00 per share (award/derivative transaction code A).

Key Details

• Transaction date: February 27, 2026; Filing date: March 3, 2026 (timely under Form 4 rules).
• Reported terms: 140,000 shares acquired at $0.00 (derivative award).
• Vesting/exercise terms (footnote): The award vests/exercises ratably in equal installments on each monthly anniversary of Feb 27, 2026 over a four-year period, subject to continued service through each vesting date.
• Shares owned following the reported transaction: not specified on the information provided in this summary.
• No immediate sale reported — this is a grant/award, not a disposition.

Context

• This is a compensation-related derivative grant that will vest monthly over four years; such awards are common for employee incentive pay and do not by themselves indicate immediate buying or selling in the market.
• Because the filing reports a derivative award (not a market purchase), retail investors should view this as standard insider compensation rather than a direct cash investment by the insider.